This is just my opinion and if you feel its repetitive just ignore it.... Mannkind already has Phase 3 results and they know both trials meet or exceed expectation. Having Phase 3 results in hand, Mannkind next secured financial arrangement with Deerfield to strengthen their negotiating position prior to restarting partnership talks. Having both Phase 3 results and Deerfield Agreement, Mannkind is now in negotiations to finalize a partnership deal. Next press release could be even better than what's expected to happen and will include not only Phase 3 results, but a signed global partnership deal. Mannkind and new Partner will move forward with powerful Phase 3 results and file an NDA re-submission. I think Mannkind and their new Partner are confidant about FDA approval based on Phase 3 results. JMO
It is likely that no one wants Al Mann for a partner. This business is built to be sold and bolted on to an existing marketing organization . It might fetch $15 after FDA approval.
But it is doubtful that any big Pharma will partner with the serial liar Al Mann.
Old, i agree al and his mgmt team are serial liars. I dont think al sells before he croaks. He wants to partner. I would have to review the deerfield agmt again, but i believe it prohibits a buyout and that's a multi-year transaction.
old.... you feeling ok son ?..better put the crack pipe down & pick up some ketamin perhaps?..your gonna need it after the results in a few weeks....
thats a promise..
this will be in the teens mid august...
then the fun really begins...
First thing, if they know the trial results, the mgmt has to disclose it as this material information. Second they cannot disclose that information only to a select investor.
If the numbers are known, why negotiate such a one-sided deal with Deerfield? Substitute 3.75% debt with 9.75 debt? Shouldn't they wait for a better deal after a month. I think the mgmt is hedging
Matt and Palumbo are selling. Go back to 2010 FDA rejection and see what happened days, weeks before that.
Pfeffer Matthew J who is Corporate VP and CFO at MANNKIND CORP sold 10,000 shares at $7.00 per share for a total value of $70,000.00 on July 2, 2013. Following this transaction, the Corporate VP and CFO owned 83,654 shares meaning that the stake was reduced by 10.68% with the 10,000 share sell-off.
The shares most recently traded at $6.93, up $0.06, or 0.87% since the insider transaction. Historical insider transactions for MannKind Corporation go as follows:
4-Week # shares bought: 9,058
4-Week # shares sold: 10,000
12-Week # shares bought: 9,058
12-Week # shares sold: 36,829
24-Week # shares bought: 9,058
24-Week # shares sold: 36,829
The average volume for MannKind Corporation has been 8.1 million shares per day over the past 30 days. MannKind Corporation has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 212.99% year to date as of the close of trading on Wednesday.